Overview

A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the superiority of ZG-801 to placebo in Japanese hyperkalemia patients whose serum potassium value becomes normal in the Run-in period by comparing the change in the value at the Double-blind period week 4, and to further evaluate the efficacy and safety of ZG-801 in Japanese hyperkalemia patients administrated ZG-801 for maximum 9 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Zeria Pharmaceutical
Treatments:
Calcium
Sorbitol